Resolving Chronic Neuropathic Pain: A Disease-Modifying Approach
| Indication | Developmental stage | Transgene | Injection route | Serotype |
|---|---|---|---|---|
| Chronic Neuropathic Pain | Preclinical | Anti-Fam19a5 scFv | Intrathecal Injection | TBD |
Moving beyond traditional daily pharmacotherapy that merely masks symptoms, the AAV gene therapy EG201 introduces a fundamentally disease-modifying approach to chronic neuropathic pain. By precisely targeting the dysregulated sensory neuron-glia signaling within the dorsal root ganglion (DRG)—a core biological driver of pain persistence—this therapy directly addresses the underlying pathology of the condition. Because a single administration drives the sustained in <i class="--italic">in vivo</i> production of a therapeutic biologic, EG201 offers a compelling value proposition: it delivers safe, durable pain control while completely freeing patients from the variable efficacy, tolerability issues, and relentless burden of daily medications.
About Chronic Neuropathic Pain
Neuropathic pain is a difficult-to-manage chronic condition arising from somatosensory nervous system lesions, leading to persistent hypersensitivity and decreased quality of life.
The DRG is a key structure where neuron-glia bidirectional signaling occurs; its dysregulation is heavily linked to persistent sensitization in chronic pain.
The Challenge of Current Therapies
Standard treatments (e.g., gabapentinoids, SNRIs) require complex, long-term daily regimens. Real-world outcomes are limited by incomplete relief and tolerability issues, driving cumulative burden and poor adherence.
This highlights the need for therapies targeting.
Our Approach: EG201
EG201 is an investigational AAV gene therapy designed to establish a mechanism-driven paradigm for chronic pain through single-dose delivery of an anti-FAM19A5 scFv. The therapy targets FAM19A5, a secreted factor implicated in the persistence of pain. FAM19A5 is proposed to regulate the association between dorsal root ganglion (DRG) neurons and satellite glial cells, and by precisely modulating this mechanism, EG201 offers a therapeutic approach distinct from conventional analgesic targets.
In preclinical rodent studies, EG201 suppressed pain-related behaviors and restored disrupted neuron–glia association in the DRG. Treated naïve animals showed no hyposensitivity, supporting a selective and safe therapeutic profile. The secreted domain of FAM19A5 and the neuron–glia architecture of the mammalian DRG are highly conserved across species, suggesting that efficacy observed in rodents is likely to translate to humans — positioning EG201 to deliver durable, mechanism-driven pain control from a single treatment.
